PGxAI Unveils Betelgeuse - New AI Model for Real-Time Clinical Outcome Analysis and Adaptive Recommendations

PALO ALTO, Calif., June 16, 2025- PGxAI, a leader in AI-powered pharmacogenetics, introduces Betelgeuse, a breakthrough model that complements the recently announced Deneb.

While Deneb focuses on optimizing drug development and clinical study design, Betelgeuse is designed to analyze clinical outcomes and rapidly adjust therapeutic recommendations.

Aimed at pharmaceutical companies, clinical research organizations, and healthcare institutions, Betelgeuse provides highly accurate, data-driven insights that can boost treatment efficacy and reduce the risk of adverse events by approximately 30%.

Previously, PGxAI launched a series of AI engines, each tackling a different layer of the precision-medicine stack. These modules progress from genotype-based risk screening to real-time outcome optimization:

Sirius- first-generation risk-classification engine that automatically flags genotypes with high risk of adverse reactions or non-response, providing the baseline layer of clinical CDS.

Vega- interprets current CPIC/DPWG guidelines on the fly and instantly generates personalized recommendations; delivers 70-fold broader gene coverage than incumbent solutions.

Deneb- biopharma-oriented module that auto-generatesPGxguidance, optimizes trial cohorts and dosing based on molecular structure and properties, trimming study time and cost.

“Today’s medicine faces a key challenge: patient responses to identical treatment protocols can vary widely,” said Dr. Mike Zack, co-founder and CEO of PGxAI. “Betelgeuse tackles this variability head-on by integrating both clinical and multi-omics data. Beyond simply predicting outcomes, the model empowers clinicians to quickly revise treatment strategies based on real-world patient data, ultimately raising the likelihood of favorable results.”

Unlike conventional platforms, which often require months for data gathering and analysis, Betelgeuse performs multilayered assessments in near real-time. The model considers a wide range of factors, from genetic markers and pharmacogenetic data to historical safety profiles and clinical outcomes in similar patient cohorts. This integrated approach not only reduces the risk of ineffective treatments but also speeds up evidence-based decision-making, paving the way for more successful therapies.

“Pharmaceutical developers and healthcare providers today are looking for revolutionary, not incremental progress,” noted Allan Gobbs, co-founder and executive chairman of PGxAI. “Betelgeuse automates the analysis of complex datasets, allowing physicians and researchers to focus on what truly matters - improving patient health. By delivering an AI-powered solution for high-precision clinical recommendations, we believe Betelgeuse will significantly enhance both the agility and the effectiveness of healthcare.”

Like other PGxAI models, Betelgeuse was developed with support from leading technology partners, including NVIDIA, InterSystems, Google, and Microsoft, ensuring seamless integration with existing healthcare and research workflows. Using both Betelgeuse and Deneb together ushers in a new era of precision medicine - from predictive analytics to real-time therapeutic adjustments based on actual patient responses.

About PGxAI

Founded in 2023 and backed by venture capital firm ATEM Capital, PGxAI is at the forefront of AI-driven precision medicine, combining real-world clinical data with advanced genomics research. The company’s proprietary AI platform personalizes drug selection, dosing, and interaction management based on each patient’s unique genetic makeup. Dr. Mike Zack, MD, PhD, a UCSF pharmacogenomics expert, serves as CEO & co-founder, alongside Allan Gobbs, a life sciences investor and executive chairman. PGxAI’s advisory board features experts from Stanford University, Thermo Fisher, and GE Healthcare. By partnering with InterSystems and leveraging cutting-edge cloud and HPC technology from leading providers, PGxAI addresses one of healthcare’s most critical needs: ensuring safe and effective treatments for every individual.

Explore our full stack or reach out via our contact form to learn how Betelgeuse fits into your workflow.